SCHEMBL3148254

SCHEMBL3148254

O=C(O)c1ccc(S(=O)(=O)N(Oc2ccc(Cl)cc2)c2ccccc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 7/20 0.54
KMT2A Q03164 4/20 0.54
MEN1 O00255 3/20 0.54
CXCR3 P49682 2/20 0.54
POLB P06746 1/20 0.49
ALDH1A1 P00352 1/20 0.48
PTGES O14684 4/20 0.47
PGR P06401 1/20 0.47
TAS2R8 Q9NYW2 1/20 0.45
ALOX15 P16050 1/20 0.45
TSHR P16473 1/20 0.45
PSEN1 P49768 1/20 0.44
PSEN2 P49810 1/20 0.44
APH1B Q8WW43 1/20 0.44
NCSTN Q92542 1/20 0.44
APH1A Q96BI3 1/20 0.44
PSENEN Q9NZ42 1/20 0.44
ALOX5 P09917 1/20 0.44
TP53 P04637 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2897962 0.90 PTGES (0.52) TAS2R14KMT2AMEN1CXCR3ALDH1A1
SCHEMBL3054754 0.87 PTGES (0.47) TAS2R14KMT2AMEN1CXCR3ALDH1A1
SCHEMBL3050794 0.87 TAS2R14 (0.54) TAS2R14KMT2AMEN1CXCR3ALDH1A1
SCHEMBL3144212 0.86 KMT2A (0.46) TAS2R14KMT2AMEN1CXCR3ALDH1A1
SCHEMBL3274948 0.84 TRPM8 (0.52)
SCHEMBL3274836 0.84 TRPM8 (0.47) TAS2R14KMT2AMEN1CXCR3PTGES
SCHEMBL3052659 0.83 TAS2R14 (0.47) TAS2R14KMT2AMEN1CXCR3POLB
SCHEMBL3144652 0.80 TAS2R14 (0.52) TAS2R14KMT2AMEN1CXCR3ALDH1A1
SCHEMBL3274404 0.80 PARP10 (0.49) POLBALDH1A1PTGESTSHRSMN1; SMN2
SCHEMBL3148221 0.79 TAS2R14 (0.50) TAS2R14KMT2AMEN1CXCR3PTGES

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2074083-B1 NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-06-19 EP disclosed
US-20100075978-A1 SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2010-03-25 US disclosed
EP-2074083-A1 NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS Richter Gedeon NYRT (HU) 2009-07-01 EP disclosed
WO-2008050168-A1 NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2008-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075978-A1 SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS BDKRB1, BDKRB2, TRPV1 TAS2R14 463/4885KMT2A 3835/4885MEN1 2128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.